Collectively, our results implicated that PARP16 may be a contributor of pathological cardiac hypertrophy at least partly via activating the IRE1α–sXBP1–GATA4 pathway, and may be regarded as a new potential target for exploring effective therapeutic interventions of pathological cardiac hypertrophy and HF. The gene discussed is PARP16; the disease is cardiac hypertrophy.